Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.1.6.13 extracted from

  • Schwartz, I.V.; Pinto, L.L.; Breda, G.; Lima, L.; Ribeiro, M.G.; Mota, J.G.; Acosta, A.X.; Correia, P.; Horovitz, D.D.; Porciuncula, C.G.; Lipinski-Figueiredo, E.; Fett-Conte, A.C.; Sobrinho, R.P.; Norato, D.Y.; Paula, A.C.; Kim, C.A.; Duarte, A.R.; Boy, R.; Leistner-Segal, S.; Burin, M.G.; Giugliani, R.
    Clinical and biochemical studies in mucopolysaccharidosis type II carriers (2009), J. Inherit. Metab. Dis., 32, 732-738.
    View publication on PubMed

Application

Application Comment Organism
medicine measurement of plasma and/or leukocyte IDS activities does not discriminate adequately between mucopolysaccharidosis type II carriers and non-carriers Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
blood plasma
-
Homo sapiens
-
leukocyte
-
Homo sapiens
-

Synonyms

Synonyms Comment Organism
IDS
-
Homo sapiens
iduronate sulfatase
-
Homo sapiens

General Information

General Information Comment Organism
physiological function mucopolysaccharidosis type II carriers show lower plasma and leukocyte IDS activities but this reduction is generally associated neither with age, changes in levels of urinary glycosaminoglycans nor with the occurrence of clinical manifestations Homo sapiens